SOC Telemed, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating SOC Telemed (NASDAQ: TLMD) for possible breaches of fiduciary duty and other violations of law in its transaction with Patient Square.

Ademi LLP alleges SOC Telemed’s financial outlook and prospects are excellent and yet SOC Telemed shareholders will receive only $104 per share. The merger agreement unreasonably limits competing bids for SOC Telemed by prohibiting solicitation of further bids, and imposing a significant penalty if SOC Telemed accepts a superior bid. SOC Telemed insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of SOC Telemed’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for SOC Telemed.